JP2022546317A5 - - Google Patents

Info

Publication number
JP2022546317A5
JP2022546317A5 JP2022511290A JP2022511290A JP2022546317A5 JP 2022546317 A5 JP2022546317 A5 JP 2022546317A5 JP 2022511290 A JP2022511290 A JP 2022511290A JP 2022511290 A JP2022511290 A JP 2022511290A JP 2022546317 A5 JP2022546317 A5 JP 2022546317A5
Authority
JP
Japan
Prior art keywords
hla
cells
mhc class
expressing
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022511290A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022546317A (ja
JP7728747B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/047639 external-priority patent/WO2021041316A1/en
Publication of JP2022546317A publication Critical patent/JP2022546317A/ja
Publication of JP2022546317A5 publication Critical patent/JP2022546317A5/ja
Priority to JP2025134675A priority Critical patent/JP2025186232A/ja
Application granted granted Critical
Publication of JP7728747B2 publication Critical patent/JP7728747B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022511290A 2019-08-23 2020-08-24 Ｃｄ２４発現細胞およびそれらの用途 Active JP7728747B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025134675A JP2025186232A (ja) 2019-08-23 2025-08-13 Ｃｄ２４発現細胞およびそれらの用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962891180P 2019-08-23 2019-08-23
US62/891,180 2019-08-23
PCT/US2020/047639 WO2021041316A1 (en) 2019-08-23 2020-08-24 Cd24 expressing cells and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025134675A Division JP2025186232A (ja) 2019-08-23 2025-08-13 Ｃｄ２４発現細胞およびそれらの用途

Publications (3)

Publication Number Publication Date
JP2022546317A JP2022546317A (ja) 2022-11-04
JP2022546317A5 true JP2022546317A5 (enExample) 2023-09-01
JP7728747B2 JP7728747B2 (ja) 2025-08-25

Family

ID=72432999

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022511290A Active JP7728747B2 (ja) 2019-08-23 2020-08-24 Ｃｄ２４発現細胞およびそれらの用途
JP2025134675A Withdrawn JP2025186232A (ja) 2019-08-23 2025-08-13 Ｃｄ２４発現細胞およびそれらの用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025134675A Withdrawn JP2025186232A (ja) 2019-08-23 2025-08-13 Ｃｄ２４発現細胞およびそれらの用途

Country Status (7)

Country Link
US (1) US20230025289A1 (enExample)
EP (1) EP4017508A1 (enExample)
JP (2) JP7728747B2 (enExample)
KR (1) KR20220068222A (enExample)
AU (1) AU2020336302A1 (enExample)
CA (1) CA3148370A1 (enExample)
WO (1) WO2021041316A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2018131403A (ru) * 2016-02-15 2020-03-17 Юниверсити Оф Саутерн Калифорния Комбинации лекарственных средств и способы стимуляции эмбрионоподобной регенерации для лечения сахарного диабета и других заболеваний
WO2018227286A1 (en) 2017-06-12 2018-12-20 Sinai Health System Allograft tolerance without the need for systemic immune suppression
US12622932B2 (en) 2018-12-13 2026-05-12 Sinai Health System Immunomodulatory cells and uses thereof
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
MX2022004373A (es) * 2019-10-10 2022-07-27 New York Stem Cell Found Inc Celulas madre modificadas y metodos de uso de las mismas.
JP2023511965A (ja) * 2020-01-23 2023-03-23 カンステム バイオテック カンパニー リミテッド Ｏｆｆ－ｔｈｅ－ｓｈｅｌｆ幹細胞および免疫細胞、それを含む薬学的組成物
US11459372B2 (en) * 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
TW202237827A (zh) 2020-12-03 2022-10-01 美商世紀治療股份有限公司 經基因工程改造之細胞及其用途
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
US11473060B2 (en) 2020-12-30 2022-10-18 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into NK cells
US20240207314A1 (en) * 2021-04-30 2024-06-27 The Board Of Trustees Of The Leland Stanford Junior University Methods to improve t cell efficacy and safety by modulating mediators of phagocytosis
BR112023024434A2 (pt) * 2021-05-27 2024-02-20 Sana Biotechnology Inc Células hipoimunogênicas que compreendem hla-e ou hla-g geneticamente modificadas
WO2022269393A1 (en) * 2021-06-23 2022-12-29 Crispr Therapeutics Ag Engineered cells with improved protection from natural killer cell killing
EP4370544A2 (en) 2021-07-14 2024-05-22 Sana Biotechnology, Inc. Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
JP2024534771A (ja) * 2021-08-11 2024-09-26 サナ バイオテクノロジー，インコーポレイテッド 補体媒介性炎症反応を低減するための同種異系細胞療法のための遺伝子改変細胞
MX2024001443A (es) 2021-08-11 2024-05-15 Sana Biotechnology Inc Sistemas inducibles para alterar la expresión génica en células hipoinmunógenas.
MX2024007528A (es) 2021-12-23 2024-08-30 Sana Biotechnology Inc Linfocitos t del receptor de antígeno quimérico (car) para el tratamiento de enfermedades autoinmunitarias y métodos asociados.
US20250302953A1 (en) 2022-02-14 2025-10-02 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
CN116804185A (zh) * 2022-03-25 2023-09-26 士泽生物医药（苏州）有限公司 一种通用型细胞及其制备方法
WO2023215455A1 (en) * 2022-05-05 2023-11-09 University Of Rochester Dual macroglial-microglial approach towards therapeutic cell replacement in neurodegenerative and neuropsychiatric disease
WO2024097315A2 (en) * 2022-11-02 2024-05-10 Sana Biotechnology, Inc. Cell therapy products and methods for producing same
CN118147077B (zh) * 2022-12-07 2025-09-26 士泽生物医药（苏州）有限公司 一种表达gsn的通用型细胞及其制备方法
JP2026501446A (ja) * 2022-12-16 2026-01-15 ゼルスマート バイオ‐ファーマシューティカル （スズホウ） シーオー．， エルティーディー． ユニバーサル細胞及びその製造方法
WO2024169917A1 (zh) * 2023-02-16 2024-08-22 士泽生物医药（苏州）有限公司 通用型细胞及其制备方法
CN121311581A (zh) * 2023-06-05 2026-01-09 士泽生物医药（苏州）有限公司 一种免疫豁免性诱导性多能干细胞分化的神经细胞及其应用
WO2025117331A1 (en) 2023-12-01 2025-06-05 Eli Lilly And Company Methods of making stem cell-derived islet-like cells, as well as populations and compositions including the same
WO2025230947A1 (en) 2024-04-30 2025-11-06 Satellite Biosciences, Inc. Engineered hepatocytes for secreting polypeptides
WO2025230941A1 (en) 2024-04-30 2025-11-06 Satellite Biosciences, Inc. Hypoimmunogenic cell mixtures and methods of use thereof
CN121046319A (zh) * 2024-05-20 2025-12-02 南京奇迹生物科技有限公司 一种降低t细胞免疫原性的方法

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422251A (en) 1986-11-26 1995-06-06 Princeton University Triple-stranded nucleic acids
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
US5674722A (en) 1987-12-11 1997-10-07 Somatix Therapy Corporation Genetic modification of endothelial cells
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5420032A (en) 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US6361996B1 (en) 1997-05-07 2002-03-26 University Of Utah Research Foundation Neuroepithelial stem cells and glial-restricted intermediate precursors
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US8263402B1 (en) 1998-10-19 2012-09-11 Cornell Research Foundation, Inc. Method for isolating and purifying oligodendrocytes and oligodendrocyte progenitor cells
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7070934B2 (en) 1999-01-12 2006-07-04 Sangamo Biosciences, Inc. Ligand-controlled regulation of endogenous gene expression
US7030215B2 (en) 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
HK1049515B (en) 1999-12-06 2006-01-13 Sangamo Biosciences Inc. Methods of using randomized libraries of zinc finger proteins for the identification of gene function
DE60143192D1 (de) 2000-02-08 2010-11-18 Sangamo Biosciences Inc Zellen zur entdeckung von medikamenten
US8273570B2 (en) 2000-05-16 2012-09-25 Riken Process of inducing differentiation of embryonic cell to cell expressing neural surface marker using OP9 or PA6 cells
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
WO2003016496A2 (en) 2001-08-20 2003-02-27 The Scripps Research Institute Zinc finger binding domains for cnn
US7262054B2 (en) 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
WO2003070171A2 (en) 2002-02-15 2003-08-28 Cornell Research Foundation, Inc. Myelination of congenitally dysmyelinated forebrains using oligodendrocyte progenitor cells
US20050101014A1 (en) 2002-07-11 2005-05-12 Keirstead Hans S. Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury
US7361635B2 (en) 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US7452718B2 (en) 2004-03-26 2008-11-18 Geron Corporation Direct differentiation method for making cardiomyocytes from human embryonic stem cells
JP4903689B2 (ja) 2004-04-08 2012-03-28 サンガモ バイオサイエンシズ インコーポレイテッド 神経障害および神経変性症状を治療するための方法と組成物
EP1737498A2 (en) 2004-04-08 2007-01-03 Sangamo Biosciences Inc. Zinc finger proteins for treatment of neuropathic pain
CN101228264B (zh) 2005-06-22 2017-12-26 阿斯特利亚斯生物治疗股份公司 使灵长类多能干细胞分化成心肌细胞系细胞
EP2650366B1 (en) 2005-10-18 2017-03-22 Precision Biosciences Rationally designed meganucleases with altered sequence specificity and DNA-binding affinity
EP2028268A1 (en) 2007-08-20 2009-02-25 Université Libre De Bruxelles Generation of neuronal cells from pluripotent stem cells
US9862925B2 (en) 2007-10-29 2018-01-09 Hadasit Medical Research Services & Development Limited Human stem cell-derived neural precursors for treatment of autoimmune diseases of the central nervous system
US8227247B2 (en) 2007-12-20 2012-07-24 Wisconsin Alumni Research Foundation Method of generating myelinating oligodendrocytes
US8728812B2 (en) 2008-04-22 2014-05-20 President And Fellows Of Harvard College Compositions and methods for promoting the generation of PDX1+ pancreatic cells
US9709553B2 (en) 2008-05-08 2017-07-18 University Of Rochester Treating myelin diseases with optimized cell preparations
WO2010008486A2 (en) 2008-06-24 2010-01-21 Parkinsons Institute Pluripotent cell lines and methods of use thereof
WO2010022395A2 (en) 2008-08-22 2010-02-25 President And Fellows Of Harvard College Methods of reprogramming cells
CN102325878A (zh) 2008-12-23 2012-01-18 斯特姆塞尔思加利福尼亚有限公司 少突胶质前体细胞的靶向细胞群及制备与使用方法
US8507274B2 (en) 2009-02-06 2013-08-13 President And Fellows Of Harvard College Compositions and methods for promoting the generation of definitive endoderm
WO2010144696A1 (en) 2009-06-11 2010-12-16 Burnham Institute For Medical Research Directed differentiation of stem cells
US9057053B2 (en) 2010-01-19 2015-06-16 The Board Of Trustees Of The Leland Stanford Junior University Direct conversion of cells to cells of other lineages
NZ603196A (en) 2010-04-28 2014-07-25 Oncolmmune Inc Methods of use of soluble cd24 for therapy of rheumatoid arthritis
EP3156062A1 (en) 2010-05-17 2017-04-19 Sangamo BioSciences, Inc. Novel dna-binding proteins and uses thereof
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
EP3399026B1 (en) 2010-06-14 2024-06-26 The Scripps Research Institute Reprogramming of cells to a new fate
SG189269A1 (en) 2010-10-26 2013-05-31 Univ Case Western Reserve Differentiation methods for production of glial cell populations
CA2829804A1 (en) 2011-03-29 2012-10-04 Geron Corporation Enriched populations of cardiomyocyte lineage cells from pluripotent stem cells
WO2012135621A2 (en) 2011-03-30 2012-10-04 Cellular Dynamics International. Inc Priming of pluripotent stem cells for neural differentiation
JP5996630B2 (ja) 2011-04-05 2016-09-21 セレクティスＣｅｌｌｅｃｔｉｓ コンパクトｔａｌｅ−ヌクレアーゼを作製する方法及びその使用
JP6388537B2 (ja) 2011-07-21 2018-09-12 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 患者由来の人工多能性幹細胞由来の心筋細胞および使用方法
US8951798B2 (en) 2011-10-13 2015-02-10 Wisconsin Alumni Research Foundation Generation of cardiomyocytes from human pluripotent stem cells
US9850463B2 (en) 2012-02-01 2017-12-26 The Regents Of The University Of California Methods of culturing retinal pigmented epithelium cells, including xeno-free production, RPE enrichment, and cryopreservation
NZ629427A (en) 2012-02-29 2016-04-29 Sangamo Biosciences Inc Methods and compositions for treating huntington’s disease
ES2688019T3 (es) 2012-06-05 2018-10-30 The Regents Of The University Of California Métodos y composiciones para la producción acelerada de células epiteliales pigmentadas retinianas a partir de células pluripotentes
WO2014124087A1 (en) 2013-02-06 2014-08-14 University Of Rochester Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders
EP3498824A1 (en) 2013-04-26 2019-06-19 Memorial Sloan-Kettering Cancer Center Cortical interneurons and other neuronal cells produced by the directed differentiation of pluripotent and multipotent cells
JP6873705B2 (ja) 2014-05-22 2021-05-19 ニューヨーク ステム セル ファウンデーション インコーポレイテッド 多能性幹細胞由来の機能性オリゴデンドロサイト、ならびにその作製方法及び使用方法
WO2015182765A1 (ja) 2014-05-30 2015-12-03 国立大学法人京都大学 低分子化合物を用いた多能性幹細胞の心筋分化誘導法
US9765299B2 (en) 2014-09-10 2017-09-19 Wisconsin Alumni Research Foundation Chemically defined albumin-free conditions for cardiomyocyte differentiation of human pluripotent stem cells
US9724432B2 (en) 2015-04-30 2017-08-08 University Of Rochester Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder
CA2988854A1 (en) 2015-05-08 2016-11-17 President And Fellows Of Harvard College Universal donor stem cells and related methods
CN108135839A (zh) 2015-08-15 2018-06-08 阿斯特利亚斯生物治疗股份公司 用于治疗白质中风的干细胞衍生的少突胶质细胞祖细胞
AU2017228466B2 (en) 2016-03-03 2023-05-25 New York Stem Cell Foundation, Inc. Microglia derived from pluripotent stem cells and methods of making and using the same
WO2017172976A1 (en) 2016-03-29 2017-10-05 The Regents Of The University Of California Methods for promoting oligodendrocyte regeneration and remyelination
WO2018093681A1 (en) 2016-11-15 2018-05-24 Neuralstem, Inc. Multipotent neural stem cells that express platelet derived growth factor (pdgf) receptor and methods of use thereof
KR20190103373A (ko) 2017-01-13 2019-09-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 면역조작된 만능 세포
CN110637083A (zh) 2017-03-20 2019-12-31 华盛顿大学 细胞及其使用和制备方法
US10391156B2 (en) * 2017-07-12 2019-08-27 Viacyte, Inc. University donor cells and related methods
WO2019191495A1 (en) * 2018-03-29 2019-10-03 Fate Therapeutics, Inc. Engineered immune effector cells and use thereof
CN119372151A (zh) 2018-07-17 2025-01-28 加利福尼亚大学董事会 从免疫工程化多能细胞分化的细胞

Similar Documents

Publication Publication Date Title
JP2022543112A5 (enExample)
US20230062612A1 (en) Safety switches for regulation of gene expression
JP6502544B2 (ja) Ｈｌａ ｇ改変された細胞および方法
Wu et al. Development of an inducible caspase-9 safety switch for pluripotent stem cell–based therapies
US20190161530A1 (en) Chimeric antigen receptor t cell compositions
US20230272429A1 (en) Modification of blood type antigens
US9228007B1 (en) Recombinant human progenitor cells, engineered human thymocytes, and engineered human T cells
CA2956385A1 (en) Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule
HK1218232A1 (zh) 使用工程化鋅指蛋白核酸酶靶向斷裂t細胞受體基因
CN114026225A (zh) 安全的免疫隐形细胞
JP2025061188A (ja) キメラサイトカイン受容体
JP2022512674A (ja) 人工トランス活性化因子による選択
JP2020535834A (ja) 遺伝子修飾されたベータ細胞による糖尿病の治療
KR20230043906A (ko) 영양 장애형 표피 수포증의 치료약
Zheng et al. Engineering of human mesenchymal stem cells resistant to multiple natural killer subtypes
IL301534A (en) A method for preparing effector cells with the desired specificity
US11723987B2 (en) Double suicide gene vector systems for stem cells
KR102906951B1 (ko) 내인성 항원 제시 기전을 이용한 저면역원성 줄기세포 및 이의 제조 방법
WO2025181283A1 (en) Cell
CN120826463A (zh) 使用工程化细胞的癌症免疫疗法
WO2021207671A1 (en) Treating autoimmune diseases with genetically modified cells
CN117343962A (zh) 免疫兼容型人多能干细胞、其制备方法及应用
Cicciarelli et al. Prospects for Designing ‘Universal’Stem Cell Lines
Gornalusse et al. 81.“Semi-Universal Donor Stem Cells” That Express a Single Class I Human Leukocyte Antigen (HLA) A* 0201 Can Present Peptides to Allorestricted CD8+ T-Cells